| __timestamp | Amphastar Pharmaceuticals, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 49315000 |
| Thursday, January 1, 2015 | 46974000 | 75043000 |
| Friday, January 1, 2016 | 47298000 | 83749000 |
| Sunday, January 1, 2017 | 50918000 | 122682000 |
| Monday, January 1, 2018 | 58044000 | 207761000 |
| Tuesday, January 1, 2019 | 63109000 | 284812000 |
| Wednesday, January 1, 2020 | 65157000 | 317875000 |
| Friday, January 1, 2021 | 68920000 | 282660000 |
| Saturday, January 1, 2022 | 66592000 | 451421000 |
| Sunday, January 1, 2023 | 80393000 | 481871000 |
Igniting the spark of knowledge
In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Amphastar Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Amphastar's SG&A expenses grew by approximately 99%, while Sarepta's surged by an astounding 878%. Despite this, Amphastar maintained a more consistent growth pattern, with expenses increasing steadily each year. In contrast, Sarepta experienced a dramatic rise, particularly between 2018 and 2023, where costs more than doubled. This divergence highlights the strategic differences in cost management between the two companies. As investors and industry analysts look to the future, understanding these trends provides valuable insights into each company's operational efficiency and strategic priorities.
Novartis AG vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
GSK plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs ADMA Biologics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and CRISPR Therapeutics AG
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Soleno Therapeutics, Inc.
Verona Pharma plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Ultragenyx Pharmaceutical Inc. vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Amphastar Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Amphastar Pharmaceuticals, Inc. vs MannKind Corporation Trends and Insights